€3.19
1.66%
L&S, Jun 28, 10:54 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Share price

$3.40
-0.27 7.36% 1M
-0.88 20.56% 6M
-0.81 19.24% YTD
-7.81 69.67% 1Y
-60.21 94.65% 3Y
-52.50 93.92% 5Y
-52.50 93.92% 10Y
Nasdaq, Closing price Fri, Jun 28 2024
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

Key figures

Market capitalization $762.64m
Enterprise Value $482.37m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.55
P/S ratio (TTM) P/S ratio 11.94
P/B ratio (TTM) P/B ratio 1.58
Sales growth (TTM) Sales growth 22.14%
Turnover (TTM) Turnover $63.88m
EBIT (operating result TTM) EBIT $-322.16m
Free cash flow (TTM) Free cash flow $-333.83m
Cash position $324.16m
EPS (TTM) EPS $-1.32
P/E ratio expected negative
P/S ratio expected 14.15
EV/Sales expected 8.95
Short interest 14.69%
Show more

Is CureVac N.V. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

CureVac N.V. Share analysis

Unlock scores for free

Analyst opinions

8 Analysts have issued a CureVac N.V. forecast:

4x Buy
50%
3x Hold
38%
1x Sell
13%

Analyst opinions

8 Analysts have issued a CureVac N.V. forecast:

Buy
50%
Hold
38%
Sell
13%

Financial data from CureVac N.V.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
64 64
22% 22%
100%
- Direct costs 181 181
24% 24%
283%
-117 -117
30% 30%
-183%
- Selling and administrative expenses 57 57
-
89%
- Research and development costs 120 120
-
188%
-294 -294
-
-460%
- Depreciation and amortization 29 29
-
45%
EBIT (operating result) EBIT -322 -322
4% 4%
-504%
Net profit -296 -296
-
-464%

Figures in millions USD.

Don't miss a thing! We will send you all news about the CureVac N.V. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

CureVac N.V. Share News

Neutral
Accesswire
6 days ago
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.
EQS
6 days ago
This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections o...
EQS
about one month ago
In der Phase-2-Studie werden die Reaktogenität, Sicherheit und Immunogenität verschiedener Dosisstufen eines modifizierten, multivalenten Impfstoffkandidaten untersucht, der für Antigene kodiert, die auf die drei von der WHO empfohlenen Grippestämme abgestimmt sind. Die Studie wird 250 gesunde jü...
More CureVac N.V. News

Company profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 1,172
Founded 2020
Website www.curevac.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now